Profile data is unavailable for this security.
About the company
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
- Revenue in EUR (TTM)246.09m
- Net income in EUR30.01m
- Incorporated1997
- Employees1.08k
- LocationEckert & Ziegler SERobert-Roessle-Str.10BERLIN 13125GermanyDEU
- Phone+49 309410840
- Fax+49 30 941084112
- Websitehttps://www.ezag.com/
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 23 Jun 2023 | 713.86k | 3.37% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 518.12k | 2.45% |
| Amundi Asset Management SA (Investment Management)as of 03 Apr 2024 | 206.94k | 0.98% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 203.96k | 0.96% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 191.33k | 0.90% |
| Groupama Asset Management SAas of 29 Sep 2023 | 185.63k | 0.88% |
| Serafin Asset Management AGas of 30 Jun 2023 | 184.67k | 0.87% |
| Lupus alpha Asset Management AGas of 30 Jun 2023 | 178.00k | 0.84% |
| Credit Suisse AGas of 31 Jan 2024 | 156.63k | 0.74% |
| Janus Henderson Investors UK Ltd.as of 29 Feb 2024 | 154.94k | 0.73% |
